Biovitrum AB and Amgen Inc. sign important agreement for the development and marketing of drugs for diabetes and other metabolic disorders, assisted by Wiggin & Dana's Biotechnology & Life Sciences Practice Group.

September 9, 2003

Amgen Inc. (NASDAQ: AMGN) and Biovitrum AB today announced that they have signed a multifaceted agreement under which Amgen receives exclusive rights to develop and commercialize Biovitrum’s small molecule 11betaHSD1 enzyme inhibitors for the treatment of metabolic diseases and certain other medical disorders.